Comet Resources Ltd is a mineral exploration company. The company's projects include the Barraba Copper Project, Santa Teresa Gold Project, and Graphite Project. It operates in one geographical segment, Australia, and one operating segment Mineral Exploration.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1947
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Morgan Stanley upgraded Charles River Laboratories (CRL) to Overweight from Equalweight and raised its price target to $220 from $185 on June 17. - The upgrade reflects a strong uptick in biopharma funding translating into proposals and bookings, benefiting CRL's leading preclinical capabilities. - Integration of artificial intelligence into early-stage drug discovery workflows and recent acquisitions are expected to provide additional growth momentum. - CLSA also upgraded CRL to Outperform from Hold, citing a more favorable regulatory environment in China.
- Therna Biosciences and Charles River have announced a collaboration to advance single-patient RNA medicines for individuals with severe, ultra-rare disorders, focusing initially on lung fibrosis and Lamb-Shaffer Syndrome. - Using Therna's AI-enabled RNA design platform, the mRNA therapeutic candidate for lung fibrosis was generated in just three days and validated in the laboratory in less than three months. - The collaboration aims to submit a single patient Investigational New Drug application and dose the first patient later this year, demonstrating an accelerated development pathway for personalized therapies. - Therna's platform combines experimental RNA biology with advanced foundation models to create optimized therapeutic RNA sequences with enhanced durability, tissue specificity, and expression properties.
• The gene therapy market is experiencing substantial growth, fueled by technological advancements, increased investments, and a deeper understanding of genetic diseases. • Key players are actively engaging in collaborations, mergers, and acquisitions to enhance their research and development capabilities and broaden their product portfolios. • Regulatory bodies like the FDA and EMA are expediting the approval process for gene therapies, acknowledging their potential in addressing unmet medical needs. • Ethical considerations and public perception surrounding gene editing, particularly germline modifications, remain critical factors influencing market dynamics and regulatory policies.
- FibroBiologics and Charles River Laboratories have entered into a master services agreement to develop and manufacture cell-based therapies for chronic diseases. - The collaboration focuses on FibroBiologics' CYWC628, a fibroblast-based spheroids product, intended for a diabetic foot ulcer (DFU) clinical trial expected to commence in 2025. - Charles River will act as the contract development and manufacturing organisation (CDMO), leveraging its testing capabilities to support FibroBiologics' regenerative medicine efforts. - The technology transfer to Charles River for current good manufacturing practice (CGMP) manufacturing has been completed, with feasibility studies confirming cell manufacturing processes.
